BBIO · BridgeBio Pharma, Inc.
$84.12
+0.10 (+0.12%)
At close · Jul 27
Market Cap
$16.48B
Shares
195.86M
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Program Authorized
$500,000,000
as of 2026-05-06
| Program Announced | Authorized | Remaining | As of | Runs Through | Source |
|---|---|---|---|---|---|
| 2026-05-06 | $500,000,000 | — | — | — | 8-K , filed 2026-05-07 |
Cash spent on buybacks by quarter
Cash deployed each quarter. Δ marks quarters derived from the company's cumulative year-to-date disclosures.
Repurchase History
| Fiscal Year Ended | Cash Spent | Source |
|---|---|---|
| 2026-03-31 YTD | $82,500,000 | 10-Q, filed 2026-05-07 |
| 2025-12-31 | $48,276,000 | 10-K, filed 2026-02-24 |
| 2024-12-31 | $0 | 10-K, filed 2026-02-24 |
| 2023-12-31 | $0 | 10-K, filed 2026-02-24 |
| 2022-12-31 | $0 | 10-K, filed 2024-02-22 |
| 2021-12-31 | $200,000,000 | 10-K, filed 2024-02-22 |
| 2020-12-31 | $75,000,000 | 10-K, filed 2023-02-23 |
Key facts
CIK
1743881
CUSIP
10806X102
13F (30d)
85 filings
84 filers
Visit website
Investor relations